Printer Friendly

CYTOGEN ANNOUNCES RESULTS COMPARING TWO CANCER IMAGING AGENTS

 PRINCETON, N.J., March 22 /PRNewswire/ -- A presurgical clinical
 study comparing two colorectal cancer imaging agents was reported
 this weekend by Cytogen Corporation (NASDAQ: CYTO) and its
 collaborators at the Eighth International Conference on Monoclonal
 Antibody Immunoconjugates for Cancer in San Diego.
 Hani A. Nabi, M.D., Ph.D., from the State University of New York at
 Buffalo, reported on a study designed to evaluate the imaging
 characteristics and safety of the intravenously administered agents.
 The trial compared 20 patients who received Indium-labeled OncoScint|
 CR372, Cytogen's intact MAb-based imaging agent for the detection of
 colorectal cancer, with 10 patients who received a Technetium-labeled
 fragment derived from the same antibody. Nabi presented results which
 showed that OncoScint CR372 detected 21 of 27 lesions (including liver
 metastases in two of three patients) for a sensitivity of approximately
 78 percent. The Technetium-labeled fragment detected two of
 eight colorectal cancer lesions, for a sensitivity of approximately
 25 percent.
 Nabi concluded, "This study demonstrates the superiority of the
 Indium-labeled, intact monoclonal antibody imaging agent over the
 corresponding Technetium-labeled fragments for the detection of primary
 and metastatic colorectal cancer. The sensitivity with Technetium is
 not only significantly lower, but the prominent bladder and kidney
 activity associated with the clearance of the Technetium-labeled
 fragment made planar and SPECT image interpretation more difficult,
 contributing to the lower sensitivity."
 Cytogen is a biopharmaceutical company engaged in the development of
 products utilizing monoclonal antibodies for the targeted delivery of
 diagnostic and therapeutic substances directly to sites of disease.
 CYTOGEN uses its patented proprietary antibody "linker" technology
 primarily to develop specific cancer diagnostic imaging and cancer
 therapeutic products.
 /delval/
 -0- 3/22/93
 /CONTACT: Mary Beals, director of Corporate Communications of
 Cytogen, 609-987-8221/
 (CYTO)
 CO: Cytogen Corporation
 ST: New Jersey
 IN: MTC
 SU:


LJ-MJ -- PH004 -- 8103 03/22/93 09:44 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 1993
Words:301
Previous Article:ROCKING HORSE CHILD CARE CENTERS OF AMERICA ANNOUNCES RECORD EARNINGS
Next Article:EXECUFIRST BANCORP, INC., PARENT OF FIRST EXECUTIVE BANK, REPORTS YEAR-END RESULTS
Topics:


Related Articles
CYTOGEN ISSUES CANCER THERAPY PHASE I RESULTS UPDATE
CYTOGEN CORPORATION ANNOUNCES DIVIDEND PAYMENT ON CONVERTIBLE EXCHANGEABLE PREFERRED STOCK
CYTOGEN AND KNOLL A.G. CO-MARKETING AGREEMENT FINALIZED
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING NON-SMALL CELL LUNG CANCER
CYTOGEN INITIATES CLINICAL TRIALS FOR IMAGING BREAST CANCER
CYTOGEN ANNOUNCES FIRST QUARTER RESULTS
CYTOGEN ANNOUNCES 1992 ANNUAL MEETING HIGHLIGHTS
CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
CYTOGEN ACQUIRES RIGHTS TO UNILEVER CANCER PROGRAM
CYTOGEN SCIENTISTS HONORED BY R&D COUNCIL OF NEW JERSEY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters